Integra LifeSciences Receives NASDAQ Notice of Compliance

PLAINSBORO, N.J., June 6, 2008 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings
Corporation (Nasdaq:IART) today announced that The NASDAQ Stock Market has
formally notified the Company that, following the filing of the Company's
Quarterly Report on Form 10-Q for the period ended March 31, 2008 with the
Securities and Exchange Commission, the Company satisfies all requirements for
continued listing on The NASDAQ Global Market and that it has determined to
continue the listing of the Company's securities on NASDAQ.

"We are pleased with NASDAQ's decision," said Stuart Essig, Integra's President
and Chief Executive Officer. "We look forward to a continued positive working
relationship with The NASDAQ Stock Market."

Integra LifeSciences Holdings Corporation, a world leader in regenerative
medicine, is dedicated to improving the quality of life for patients through the
development, manufacturing, and marketing of cost-effective surgical implants
and medical instruments. Our products, used primarily in neurosurgery, extremity
reconstruction, orthopedics and general surgery, are used to treat millions of
patients every year. Integra's headquarters are in Plainsboro, New Jersey, and
we have research and manufacturing facilities throughout the world. Please visit
our website at (http://www.Integra-LS.com).

IART-G

-0-
CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President Finance and
Administration and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Kathryn Lamping, Assistant General Counsel
(609) 936-2276
kathryn.lamping@Integra-LS.com